Angiotensin II antagonism: a new avenue of hypertension management.
Receptor-level blockade of angiotensin II (AII) has emerged as a new therapeutic principle in cardiovascular medicine. Experience with losartan, the first of the selective AII receptor antagonists to be approved for clinical use, indicates that this approach is efficacious in all grades of hypertension and offers a more attractive and acceptable tolerability profile than other forms of antihypertensive medications. Recent clinical trial data indicate that losartan may also be beneficial in heart failure in older patients, though the drug is not yet approved for this indication.
Gavras
H
H
Boston University School of Medicine, USA.
D000368:Aged; D000804:Angiotensin II / Q000037:antagonists & inhibitors*; D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000097:blood / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007093:Imidazoles / Q000097:blood / Q000627:therapeutic use*; D019808:Losartan; D013777:Tetrazoles / Q000097:blood / Q000627:therapeutic use*
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D007093:Imidazoles; D013777:Tetrazoles; D000804:Angiotensin II; D019808:Losartan